ArticleJMIR research protocols2026
Evaluation of the Antimicrobial Efficacy of Cerium Oxide Nanoparticles and Chlorhexidine Gluconate Against Enterococcus faecalis in Root Canal Systems: Protocol for an In Vitro Study.
Article in JMIR research protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnterococcus faecalis is a facultative anaerobic bacterium frequently associated with persistent root canal infections and endodontic treatment failures. Its resistance is primarily attributed to its ability to form robust biofilms, survive under harsh conditions, and penetrate deep into dentinal tubules. Chlorhexidine gluconate (CHX), commonly used as an intracanal medicament, exhibits broad-spectrum antimicrobial activity; however, its limited ability to eliminate biofilms, potential cytotoxicity, and restricted dentinal penetration pose significant drawbacks. In recent years, nanotechnology has introduced promising alternatives such as cerium oxide nanoparticles (CeO
objectiveThis study aims to evaluate and compare the antimicrobial efficacy of 0.05% CeO
methodsForty-eight extracted human single-rooted premolars will be decoronated, instrumented, and sterilized. The root canals will be inoculated with E. faecalis and incubated for 21 days to allow biofilm formation. The specimens will then be divided into four groups (n=12 per group), each receiving one of the following treatments: (1) 0.05% CeO
resultsEthics approval was obtained from the institutional ethics committee of Datta Meghe Institute of Higher Education and Research, Wardha (approval DMIHER(DU)/IEC/2025/546) in January 2025. As of January 2026, laboratory procedures, including specimen preparation, microbial inoculation, and data collection, have not yet commenced. Data collection is planned to begin in February 2026 and is expected to be completed by April 2026. Data analysis will follow immediately thereafter, with results anticipated to be submitted for publication in mid-2026. As this is an in vitro study, no participant recruitment, funding allocation, or clinical trial registration is applicable. It is expected that the combination of CeO
conclusionsThis study aims to provide insight into the antimicrobial potential of CeO INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/77998.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.